Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Multi-Center, Double-Blind, Randomized Vehicle-Controlled Study Assessing the PK , Pharmacodynamics, Safety and Tolerability of SB414 in Subjects With Atopic Dermatitis

Trial Profile

A Phase 1b Multi-Center, Double-Blind, Randomized Vehicle-Controlled Study Assessing the PK , Pharmacodynamics, Safety and Tolerability of SB414 in Subjects With Atopic Dermatitis

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2018

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Atopic dermatitis
  • Focus Biomarker; Pharmacokinetics
  • Sponsors Novan Inc
  • Most Recent Events

    • 11 Dec 2018 According to a Novan media release, data from this trial will be presented at the 3rd Inflammatory Skin Disease Summit in Vienna, Austria.
    • 06 Sep 2018 Status changed from active, no longer recruiting to completed.
    • 20 Aug 2018 According to a Novan media release, data will be submitted for presentation by Drs. Guttman and Maeda-Chubachi at upcoming scientific and medical meetings.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top